How does ICER plan to find out whether or not well being plans supply honest entry to prescription drugs? I summarized their strategy final 12 months as outlined of their white paper titled “Cornerstones of ‘Truthful’ Drug Protection: Acceptable Price-Sharing and Utilization Administration Insurance policies for Prescribed drugs.” Final month, closing protocol for his or her “Limitations to Truthful Entry Evaluation“. Whereas the strategy follows their earlier protocol and white paper, not all all the standards on this white paper are being evaluated. Which standards is ICER evaluating? I've summarized the standards ICER plans to incorporate and exclude of their “Truthful Entry” evaluation beneath.
ICER’s 2022 “Limitations to Truthful Entry Evaluation” Protocol – Healthcare Economist